Skip to main content
Premium Trial:

Request an Annual Quote

Lumera's Q1 Sales Surge 70 Percent as Losses Narrow; Firm Extends ISB Alliance

NEW YORK (GenomeWeb News) — Lumera yesterday said first-quarter revenues increased 71 percent as R&D spending fell 20 percent and net loss narrowed 15 percent.
 
Total receipts for the three months ended March 31 increased to $860,000 from $503,000 million year over year.
 
Lumera also said it had just over $2 million in backlogged government contracts at the end of the quarter.
 
R&D spending dipped to $1.3 million from $1.6 million in the year-ago period.
 
Lumera said net loss fell to $2.7 million from $3.1 million in the year-ago period. 
  
Lumera said it had around $5.4 million in cash and cash equivalents and $18.7 million in available-for-sale securities as of March 31.
 
Separately yesterday, Lumera said it has extended an agreement with the Institute for Systems Biology, which uses the company’s ProteomicProcessor to identify biomarkers associated with drug toxicity and cancer.
 
Lumera said the tool analyzes antibodies used by an ISB-developed label-free assay that works with Lumera’s NanoCapture-Gold microarray.
 
Lumera and ISB last extended proteomics research agreement in October 2006.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.